The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•29 June 2026•

1 min read

REGENXBIO Announces First Patient Dosed in Phase IIb/III Trial for Diabetic Retinopathy; Receives $100M

Key Facts

1First patient dosed in Phase IIb/III NAAVIGATE trial of surabgene lomparvovec (ABBV-RGX-314) for diabetic retinopathy using suprachoroidal delivery.

2Company to receive a $100 million milestone payment.

As gene therapy for eye diseases gains momentum, REGENXBIO has announced a key clinical milestone. According to reports, the first patient has been dosed in the Phase IIb/III NAAVIGATE trial of surabgene lomparvovec (ABBV-RGX-314) for diabetic retinopathy using suprachoroidal delivery. The milestone triggers a $100 million payment to the company. Additionally, long-term data from diabetic retinopathy and wet AMD programs will be presented at the American Society of Retina Specialists (ASRS) 2026 meeting.

RGNX shares closed at $10.48 on June 26, within a range of $9.94 to $10.78, per market data. The drug candidate is being developed in collaboration with AbbVie, underscoring the commercial potential. The $100 million milestone bolsters REGENXBIO's balance sheet as it advances pivotal-stage trials.

Currently trading near $10.48 (close June 26), RGNX finds support around $9.94 and resistance near $10.78. Key near-term catalysts include the ASRS 2026 data presentation and any updates from the AbbVie collaboration. The milestone payment provides additional financial flexibility for ongoing clinical programs.